46
Participants
Start Date
September 30, 2016
Primary Completion Date
September 12, 2018
Study Completion Date
September 12, 2018
Rovalpituzumab Tesirine
Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
Roswell Park Cancer Institute, Buffalo
Greenville Health System Cancer Institute, Greenville
Winship Cancer Institute, Emory University, Atlanta
Baptist Health Lexington, Lexington
University Hospitals Case Medical Center, Cleveland
MetroHealth Medical Center, Cleveland
University of Cincinnati, Cincinnati
Parkview Research Center, Fort Wayne
Karmanos Cancer Institute, Detroit
Henry Ford Hospital, Detroit
University of Chicago Medical Center, Chicago
Mary Crowley Medical Research Center, Dallas
University of California Los Angeles, Los Angeles
Cross Cancer Institute, Edmonton
The Ottawa Hospital-Cancer Centre, Ottawa
Lead Sponsor
Stemcentrx
INDUSTRY